Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation
Clinical trial NCT03683433 · RECRUITING
Trial details
- NCT number
- NCT03683433
- Sponsor
- M.D. Anderson Cancer Center
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-09-18
- Primary completion
- 2027-09-20
- Enrollment
- 50
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.